Webcasted telephone conference: Immunovia reports historical breakthrough in early detection of pancreatic cancer in high risk groups

Tuesday, March 30 2021, at 16:30 CET

Presentations by: Patrik Dahlen, CEO, Thomas King, MD, PhD, Linda Mellby, PhD, Immunovia

Immunovia reports positive results of the blinded clinical validation of IMMray™ PanCan-d blood test for Stage I/II pancreatic cancers in familial/hereditary risk groups in USA – and improved test performance in detecting early stage pancreatic cancer in high risk symptomatic patients.


Immunovia’s IMMray™ PanCan-d Webinar Series

Thursday, December 17, 2020 at 15:00 CET

Webinar No. 3: IMMray™ PanCan-d Verification study and Clinical Use

Presentations by: Thomas King, MD, PhD, Linda Mellby, PhD, Laura Chirica, PhD, Immunovia

Moderator: Patrik Dahlen, CEO Immunovia

Immunovia interview with Prof. Stephen Pereira, Gastroenterologist and Hepatologist, BSc, PhD, FRCP, FRCPE, at the London Clinic (UCL), Principle Investigator for Immunovia´s PanSYM study in London, UK, in regard to the clinical utility of diagnostic tests in pancreatic cancer, December 8, 2020.



Wednesday, September 2, 2020 at 16:00 CET

Webinar No. 2: Commercial Test Model Study & Update on Launch Activities

Presenters: Linda Mellby, PhD; Laura Chirica, PhD and Thomas King, MD, PhD


Immunovia’s Virtual Investor Day, Tuesday, June 30, 2020

The online event features presentations by Immunovia’s Chairman, Carl Borrebaeck; CEO, Mats Grahn; Chief Commercial Officer, Laura Chirica; Senior VP Sales North America, Michael Pettigrew; and Dr Thomas King, Medical Director, followed by a Q&A session.


Immunovia Presentation  – PDF version


Monday, September 9, 2019 at 18:30 CET

Webinar No. 1: Differentiating Pancreatic Ductal Adenocarcinoma (PDAC) from individuals with symptoms suggestive of PDAC, including type II diabetes, with ROC AUC values above 0.95

Presenters: Linda Mellby, PhD and Thomas King, MD, PhD, Immunovia



Subscribe to receive press releases and reports via email
To start your subscription you need to activate your e-mail address by clicking the link in the email that is sent to you after you have submitted this form. Please check the junk mail if you cannot find the message.

Press releases
Financial reports